BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Fintel reports that on October 31, 2024, William Blair downgraded their outlook for Altair Engineering (NasdaqGS:ALTR) from ...

William Blair analysts on Monday raised their revenue and profit estimates for Nvidia over the next two fiscal years, citing ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) ...

Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.

William Blair analyst Louie DiPalma has maintained their bearish stance on PLTR stock, giving a Sell rating yesterday. Louie DiPalma has given ...

On Friday, William Blair issued an upgrade for argenx SE (NASDAQ: ARGX) stock, raising its rating from Market Perform to Outperform. The firm's optimism stems from the success of argenx's Vyvgart ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth.

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...